ClinicalTrials.gg
CompletedNCT00413049Updated Apr 29, 2011Results posted

Efficacy/Safety of Valsartan Plus Amlodipine and Amlodipine Alone in Patients With Hypertension

A Phase 3 interventional study of Valsartan/amlodipine 80/5 mg and Amlodipine 5 mg in Hypertension, sponsored by Novartis. Completed at 12 sites in China. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2011-04-29.

Sponsored by Novartis · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
698
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 228 studies in Hypertension by Novartis — 5 open to participants now, 6 under way, none of them phase 3. Hypertension · Novartis.

Enrollment
54th of 223
698 · median 300
Started
2007
with 16 others
Phase 3
108 of 228
none open now
Registered
103rd of 228
by date

Among the 228 studies in Hypertension by Novartis, this one is the 54th largest by enrollment of the 223 interventional ones that give a count, is one of 17 that started in 2007, is one of 108 in phase 3, and was the 103rd registered.

Hypertension

6,128 studies on the registry are indexed under Hypertension; 911 are open to participants now.

Browse Hypertension studies →

Open to participants now

5 of the 228 studies in Hypertension by Novartis are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 556 Hypertension studies recruiting now, 262 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 137 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 228 studies in Hypertension by Novartis, or all of them as a file.
02

Study summary

This study will evaluate the safety and efficacy of the fixed combination of valsartan/amlodipine in adult patients with mild to moderate hypertension

03

Conditions studied

  • Hypertension

Browse trials for

Keywords

  • Hypertension, valsartan, amlodipine, high blood pressure
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female outpatients ≥ 18 years and \< 86 years
  • Patients with essential hypertension measured by calibrated mercury sphygmomanometer (preferred) or an aneroid device if a mercury sphygmomanometer was not available.
  • At Visit 1, patients not treated with antihypertensive medications had to have a MSDBP of ≥ 95 mmHg and \< 110 mmHg; those patients treated with antihypertensive medication had to have a MSDBP of \< 110 mmHg.
  • At Visit 2, patients must have a MSDBP of ≥ 95 mmHg but \< 110 mmHg.
  • At Visit 3, patients must have a MSDBP of ≥ 90 mmHg and \< 110 mmHg.
  • Patients who were eligible and able to participate in the study, and who consented to do so after the purpose and nature of the investigation had been clearly explained to them (written ).

Exclusion criteria

Exclusion criteria

  • Severe hypertension (MSDBP ≥ 110 mmHg and/or MSSBP ≥ 180 mmHg).
  • In cases where the patient was on more than one antihypertensive drug whether in fixed or free combination, the investigator considered the efficacy and strength of each active ingredient in order to determine if the patient could be safely removed from their antihypertensive treatment.
  • Known or suspected , including history of allergy or to angiotensin receptor blockers (ARB), calcium channel blockers (CCB), or to drugs with similar chemical structures.
  • Administration of any agent indicated for the treatment of hypertension after Visit 1 with the exception of those agents that required tapering down.
  • Inability to discontinue all prior antihypertensive medications safely for a maximum period of up to 28 days prior to Visit 2, as required by the protocol.
  • History of hypertensive encephalopathy, cerebrovascular accident or , myocardial infarction or all types of revascularization.
  • Malignant hypertension.
  • All patients with Type 1 diabetes mellitus and those patients with Type 2 diabetes mellitus who were not well controlled based on the investigator's clinical judgment. Patients being treated for diabetes mellitus had to have satisfactory metabolic control. Type 2 diabetic patients taking oral anti-diabetic medication had to be on a stable dose for at least 4 weeks prior to Visit 1.
  • Pregnant or nursing (lactating) women, where pregnancy was defined as the state of a female after conception and until the termination of gestation, confirmed by a positive human chorionic gonadotropin (hCG) laboratory test (> 5 mIU/ml).
  • Women of (WOCBP), defined as all women physiologically capable of becoming pregnant, including women whose career, lifestyle, or sexual orientation precluded intercourse with a male partner and women whose partners had been sterilized by vasectomy or other means, UNLESS they met the following definition of : 12 months of natural (spontaneous) amenorrhea or 6 months of spontaneous amenorrhea with serum follicle stimulating hormone (FSH) levels > 40 mIU/m or 6 weeks post-surgical bilateral oophorectomy with or without hysterectomy OR were using one or more of the following acceptable methods of : surgical sterilization (e.g., bilateral tubal ligation, vasectomy), and double-barrier methods (any double combination of: intra-uterine device [IUD], male or female condom with spermicidal gel, diaphragm, sponge, cervical cap). Acceptable methods of contraception included total abstinence at the discretion of the investigator in cases where the age, career, lifestyle, or sexual orientation of the patient ensured compliance. Reliable contraception had to be maintained throughout the study and for 7 days after study drug discontinuation. Periodic abstinence (eg, calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal were not acceptable methods of contraception. Hormonal contraceptive use was disallowed.
  • History of heart failure Grade II-IV according to the (NYHA) classification.
  • Second or third degree heart block with or without a pacemaker.
  • Concomitant potentially life threatening arrhythmia or symptomatic arrhythmia.
  • Angina pectoris of any type, including unstable angina pectoris.
  • valvular heart disease.
  • Evidence of a secondary form of hypertension, including but not limited to any of the following: coarctation of the aorta, hyperaldosteronism, unilateral or bilateral renal artery stenosis, Cushing disease, pheochromocytoma, polycystic kidney disease.
  • Known moderate or malignant retinopathy, defined as: moderate (retinal signs of hemorrhage, microaneurysm, cotton-wool spot, hard exudates, or a combination thereof) or (signs of moderate retinopathy plus swelling of the optic disk).
  • Evidence of hepatic disease as determined by any one of the following: (AST) or alanine aminotransferase (ALT) values greater than two times the at Visit 1, a history of hepatic encephalopathy, a history of esophageal varices, or a history of a portocaval shunt.
  • Evidence of renal impairment as determined by anyone of the following: serum creatinine > 1.5 times the upper limit of normal at Visit 1, a history of dialysis, or a history of nephrotic syndrome.
  • History of clinically significant allergies including asthma, and/or multiple drug allergies.
  • Any surgical or medical condition with the potential to significantly alter the absorption, distribution, metabolism, or excretion of any drug including but not limited to any of the following: history of major gastrointestinal tract surgery such as gastrectomy, gastroenterostomy, bowel resection, gastric bypass, gastric stapling, or gastric banding, currently active or active inflammatory bowel syndrome within 12 months prior to Visit 1, currently active gastritis, ulcers, or gastrointestinal/rectal bleeding, or urinary tract obstruction regarded as clinically meaningful by the investigator.
  • Any surgical or medical condition, which in the opinion of the investigator or the Novartis monitor, placed the patient at higher risk from his/her participation in the study, or were likely to prevent the patient from complying with the requirement of the study or completing the trial period.
  • Volume depletion based on the investigator's clinical judgment using vital signs, skin turgor, moistness of mucous membranes, and laboratory values.
  • Any chronic inflammatory condition requiring chronic anti-inflammatory therapy.
  • History of malignancy of any organ system, treated or untreated, within the past 5 years whether or not there was evidence of local recurrence or , with the exception of localized basal cell carcinoma of the skin.
  • History of drug of alcohol abuse within the last 2 years.
  • Use of other drugs at the time of enrollment, or within 30 days or 5 half-lives of enrollment, whichever was longer.
  • Inability to communicate and comply with all study requirements including the unwillingness or inability to provide .
  • Persons directly involved in the execution of this protocol.
  • History of non-compliance to medical regimens, or unwillingness to comply with the study protocol.
  • Currently taking prohibited concomitant medications(s) listed and inability/unwillingness to discontinue them for the entire study period.
  • Any severe, life-threatening disease within the past five years.
  • Arm circumference > 42 cm for patients participating in ambulatory blood pressure monitoring (ABPM).
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
698 participants (actual)

Study arms

  • Experimental
    Valsartan/amlodipine 80/5 mg

    Drug: Valsartan/amlodipine 80/5 mg

  • Active comparator
    Amlodipine 5 mg

    Drug: Amlodipine 5 mg

Interventions

  • DrugValsartan/amlodipine 80/5 mg

    1 valsartan/amlodipine 80/5 mg tablet and 1 placebo capsule matching amlodipine 5 mg to be taken with water at approximately 8:00 a.m. once daily, except on the morning of every scheduled study visit, when study drug was taken after the completion of all other study procedures.

  • DrugAmlodipineStudies of AmlodipineAmlodipine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    1 amlodipine 5 mg capsule and 1 placebo tablet matching valsartan/amlodipine 80/5 mg to be taken with water at approximately 8:00 a.m. once daily, except on the morning of every scheduled study visit, when study drug was taken after the completion of all other study procedures.

06

What researchers measure

Primary outcomes

  1. Change in Mean Sitting Diastolic Blood Pressure (msDBP) From Baseline to End of Study (Week 8)

    Blood pressure (BP) was measured with a calibrated aneroid or mercury sphygmomanometer. The arm in which the highest sitting diastolic BP was found at study entry was used for all subsequent readings. At each visit, after the patient was in a sitting position for five minutes, systolic/diastolic BP was measured 3 times at 1-2-minute intervals. The mean of the 3 measurements was calculated. A negative change score indicates lowered BP.

    Time frame: Baseline to end of study (Week 8)

Secondary outcomes

  1. Change in Mean Sitting Systolic Blood Pressure (msSBP) From Baseline to End of Study (Week 8)

    Blood pressure (BP) was measured with a calibrated aneroid or mercury sphygmomanometer. The arm in which the highest sitting diastolic BP was found at study entry was used for all subsequent readings. At each visit, after the patient was in a sitting position for five minutes, systolic/diastolic BP was measured 3 times at 1-2-minute intervals. The mean of the 3 measurements was calculated. A negative change score indicates lowered BP.

    Time frame: Baseline to end of study (Week 8)

  2. Percentage of Patients Achieving a Diastolic Response at the End of the Study (Week 8)

    A patient achieved a diastolic response if their msDBP \< 90 mmHg at Week 8 or they had a ≥ 10 mmHg decrease in msDBP compared to baseline at the end of the study (Week 8). Blood pressure (BP) was measured with a calibrated aneroid or mercury sphygmomanometer. The arm in which the highest sitting diastolic BP was found at study entry was used for all subsequent readings. At each visit, after the patient was in a sitting position for five minutes, systolic/diastolic BP was measured 3 times at 1-2-minute intervals. The mean of the 3 measurements was calculated.

    Time frame: Baseline to end of study (Week 8)

  3. Percentage of Patients Achieving Diastolic Control at the End of the Study (Week 8)

    A patient achieved diastolic control if their msDBP \< 90 mmHg at the end of the study (Week 8). Blood pressure (BP) was measured with a calibrated aneroid or mercury sphygmomanometer. The arm in which the highest sitting diastolic BP was found at study entry was used for all subsequent readings. At each visit, after the patient was in a sitting position for five minutes, systolic/diastolic BP was measured 3 times at 1-2-minute intervals. The mean of the 3 measurements was calculated.

    Time frame: Baseline to end of study (Week 8)

  4. Percentage of Patients Achieving Overall Control at the End of the Study (Week 8)

    A patient achieved overall control if the msSBP/msDBP \< 140/90 mmHg at the end of the study (Week 8). Blood pressure (BP) was measured with a calibrated aneroid or mercury sphygmomanometer. The arm in which the highest sitting diastolic BP was found at study entry was used for all subsequent readings. At each visit, after the patient was in a sitting position for five minutes, systolic/diastolic BP was measured 3 times at 1-2-minute intervals. The mean of the 3 measurements was calculated.

    Time frame: Baseline to end of study (Week 8)

  5. Change in 24-hour Mean Ambulatory Diastolic and Systolic BP From Baseline at the End of the Study (Week 8)

    Two 24 hour ambulatory blood pressure monitoring (ABPM) evaluations were performed, one at baseline prior to randomization and one at Week 8 (end of study), in a subset of the intent-to-treat population of patients. For each evaluation, the ABPM device was attached to the non-dominant arm of the patient. A correlation was made between the ABPM device readings and measurements taken with a mercury sphygmomanometer and stethoscope. Following the correlation procedure, BP was measured at study specified intervals. A negative change score indicates lowered BP.

    Time frame: Baseline to end of study (Week 8)

07

Results

Posted Feb 8, 2011

Participant flow

Participant flow — Overall Study
MilestoneValsartan/Amlodipine 80/5 mgAmlodipine 5 mg
Started349349
Completed325331
Not completed2418
Withdrew: Adverse event108
Withdrew: Withdrawal by subject75
Withdrew: Lost to follow-up23
Withdrew: Protocol violation31
Withdrew: Subject no longer requires study drug01
Withdrew: Abnormal laboratory value(s)10
Withdrew: Lack of efficacy10

Outcome measures

PrimaryChange in Mean Sitting Diastolic Blood Pressure (msDBP) From Baseline to End of Study (Week 8)

Blood pressure (BP) was measured with a calibrated aneroid or mercury sphygmomanometer. The arm in which the highest sitting diastolic BP was found at study entry was used for all subsequent readings. At each visit, after the patient was in a sitting position for five minutes, systolic/diastolic BP was measured 3 times at 1-2-minute intervals. The mean of the 3 measurements was calculated. A negative change score indicates lowered BP.

Time frame:
Baseline to end of study (Week 8)
Reported as:
Least squares mean · mmHg
Change in Mean Sitting Diastolic Blood Pressure (msDBP) From Baseline to End of Study (Week 8)
mmHgValsartan/Amlodipine 80/5 mgAmlodipine 5 mg
Change in Mean Sitting Diastolic Blood Pressure (msDBP) From Baseline to End of Study (Week 8)-9.7 ± 0.42-7.1 ± 0.42
SecondaryChange in Mean Sitting Systolic Blood Pressure (msSBP) From Baseline to End of Study (Week 8)

Blood pressure (BP) was measured with a calibrated aneroid or mercury sphygmomanometer. The arm in which the highest sitting diastolic BP was found at study entry was used for all subsequent readings. At each visit, after the patient was in a sitting position for five minutes, systolic/diastolic BP was measured 3 times at 1-2-minute intervals. The mean of the 3 measurements was calculated. A negative change score indicates lowered BP.

Time frame:
Baseline to end of study (Week 8)
Reported as:
Least squares mean · mmHg
Change in Mean Sitting Systolic Blood Pressure (msSBP) From Baseline to End of Study (Week 8)
mmHgValsartan/Amlodipine 80/5 mgAmlodipine 5 mg
Change in Mean Sitting Systolic Blood Pressure (msSBP) From Baseline to End of Study (Week 8)-11.4 ± 0.61-7.4 ± 0.60
SecondaryPercentage of Patients Achieving a Diastolic Response at the End of the Study (Week 8)

A patient achieved a diastolic response if their msDBP \< 90 mmHg at Week 8 or they had a ≥ 10 mmHg decrease in msDBP compared to baseline at the end of the study (Week 8). Blood pressure (BP) was measured with a calibrated aneroid or mercury sphygmomanometer. The arm in which the highest sitting diastolic BP was found at study entry was used for all subsequent readings. At each visit, after the patient was in a sitting position for five minutes, systolic/diastolic BP was measured 3 times at 1-2-minute intervals. The mean of the 3 measurements was calculated.

Time frame:
Baseline to end of study (Week 8)
Reported as:
Number · Percentage of patients
Percentage of Patients Achieving a Diastolic Response at the End of the Study (Week 8)
Percentage of patientsValsartan/Amlodipine 80/5 mgAmlodipine 5 mg
Percentage of Patients Achieving a Diastolic Response at the End of the Study (Week 8)79.366.8
SecondaryPercentage of Patients Achieving Diastolic Control at the End of the Study (Week 8)

A patient achieved diastolic control if their msDBP \< 90 mmHg at the end of the study (Week 8). Blood pressure (BP) was measured with a calibrated aneroid or mercury sphygmomanometer. The arm in which the highest sitting diastolic BP was found at study entry was used for all subsequent readings. At each visit, after the patient was in a sitting position for five minutes, systolic/diastolic BP was measured 3 times at 1-2-minute intervals. The mean of the 3 measurements was calculated.

Time frame:
Baseline to end of study (Week 8)
Reported as:
Number · Percentage of patients
Percentage of Patients Achieving Diastolic Control at the End of the Study (Week 8)
Percentage of patientsValsartan/Amlodipine 80/5 mgAmlodipine 5 mg
Percentage of Patients Achieving Diastolic Control at the End of the Study (Week 8)75.564.5
SecondaryPercentage of Patients Achieving Overall Control at the End of the Study (Week 8)

A patient achieved overall control if the msSBP/msDBP \< 140/90 mmHg at the end of the study (Week 8). Blood pressure (BP) was measured with a calibrated aneroid or mercury sphygmomanometer. The arm in which the highest sitting diastolic BP was found at study entry was used for all subsequent readings. At each visit, after the patient was in a sitting position for five minutes, systolic/diastolic BP was measured 3 times at 1-2-minute intervals. The mean of the 3 measurements was calculated.

Time frame:
Baseline to end of study (Week 8)
Reported as:
Number · Percentage of patients
Percentage of Patients Achieving Overall Control at the End of the Study (Week 8)
Percentage of patientsValsartan/Amlodipine 80/5 mgAmlodipine 5 mg
Percentage of Patients Achieving Overall Control at the End of the Study (Week 8)69.257.6
SecondaryChange in 24-hour Mean Ambulatory Diastolic and Systolic BP From Baseline at the End of the Study (Week 8)

Two 24 hour ambulatory blood pressure monitoring (ABPM) evaluations were performed, one at baseline prior to randomization and one at Week 8 (end of study), in a subset of the intent-to-treat population of patients. For each evaluation, the ABPM device was attached to the non-dominant arm of the patient. A correlation was made between the ABPM device readings and measurements taken with a mercury sphygmomanometer and stethoscope. Following the correlation procedure, BP was measured at study specified intervals. A negative change score indicates lowered BP.

Time frame:
Baseline to end of study (Week 8)
Reported as:
Mean · mmHg
Change in 24-hour Mean Ambulatory Diastolic and Systolic BP From Baseline at the End of the Study (Week 8)
mmHgValsartan/Amlodipine 80/5 mgAmlodipine 5 mg
Diastolic BP-6.3 ± 5.850.3 ± 5.82
Systolic BP-7.3 ± 7.62-0.2 ± 8.64

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Valsartan/Amlodipine 80/5 mg—4/349 (1.1%)0/349 (0%)
Amlodipine 5 mg—2/349 (0.6%)0/349 (0%)
Most frequent serious events
Most frequent serious events
EventValsartan/Amlodipine 80/5 mgAmlodipine 5 mg
Gastric ulcerGastrointestinal disorders1/3491/349
Humerus fractureInjury, poisoning and procedural complications1/3490/349
Jaw cystMusculoskeletal and connective tissue disorders1/3490/349
Parathyroid tumour benignNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/3491/349
Post herpetic neuralgiaNervous system disorders1/3490/349

Baseline characteristics

Age Continuous
Age Continuous(years)Valsartan/Amlodipine 80/5 mgAmlodipine 5 mgTotal
Mean53.4 ± 9.754.2 ± 9.153.8 ± 9.4
Sex: Female, Male
Sex: Female, Male(Participants)Valsartan/Amlodipine 80/5 mgAmlodipine 5 mgTotal
Female134109243
Male213240453
08

Study locations

12 sites
  • China-Japan Friendship Hospital
    Beijing, 100029, China
  • People's hospital affiliated Beijing University
    Beijing, 100044, China
  • The third Xiangya hospital of central south University
    Changsha, 410003, China
  • The first hospital affiliated the third military Medical University
    Chongqing, 400038, China
  • The third hospital affiliated the third military Medical University
    Chongqing, 400042, China
  • Union hospital affiliated Fujian medical University
    Fuzhou, 350001, China
  • The first hospital affiliated Fujian medical University
    Fuzhou, 350005, China
  • The second hospital affiliated Jiangxi medical school
    Nanchang, 330006, China
  • Institute of Hypertension, Ruijin Hospital
    Shanghai, 200025, China
  • Zhongshan hospital affiliated Fudan University
    Shanghai, 200032, China
  • The sixth people's hospital of Shanghai
    Shanghai, 200233, China
  • The first hospital affiliated school of medical of Xi'an Jiaotong University
    Xi'an, 710061, China
09

References and documents

Publications

  • Ke Y, Zhu D, Hong H, Zhu J, Wang R, Cardenas P, Zhang Y. Efficacy and safety of a single-pill combination of amlodipine/valsartan in Asian hypertensive patients inadequately controlled with amlodipine monotherapy. Curr Med Res Opin. 2010 Jul;26(7):1705-13. doi: 10.1185/03007995.2010.487391. PubMed 20469975 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2007, a primary completion of Nov 2007 and a completion of Nov 2007. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2011, 3 years 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 18, 2006
First posted
Dec 19, 2006
Start
Jan 2007
Primary completionActual
Nov 2007
CompletionActual
Nov 2007
Results first posted
Feb 8, 2011
Last update
Apr 29, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 29, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00413049
Lead sponsor
Novartis
First posted
Dec 19, 2006
Start date
Jan 2007
Primary completion
Nov 2007
Completion
Nov 2007
Results posted
Feb 8, 2011
Last update
Apr 29, 2011

Study contacts

Novartis Pharmaceuticals
study director · Sponsor GmbH
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion